<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35322729</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1475-6374</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>37</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of enzyme inhibition and medicinal chemistry</Title>
          <ISOAbbreviation>J Enzyme Inhib Med Chem</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Biological investigation of <i>N</i>-methyl thiosemicarbazones as antimicrobial agents and bacterial carbonic anhydrases inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>986</StartPage>
          <EndPage>993</EndPage>
          <MedlinePgn>986-993</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/14756366.2022.2055009</ELocationID>
        <Abstract>
          <AbstractText>The enormous burden of the COVID-19 pandemic in economic and healthcare terms has cast a shadow on the serious threat of antimicrobial resistance, increasing the inappropriate use of antibiotics and shifting the focus of drug discovery programmes from antibacterial and antifungal fields. Thus, there is a pressing need for new antimicrobials involving innovative modes of action (MoAs) to avoid cross-resistance rise. Thiosemicarbazones (TSCs) stand out due to their easy preparation and polypharmacological application, also in infectious diseases. Recently, we reported a small library of TSCs (<b>1-9</b>) that emerged for their non-cytotoxic behaviour. Inspired by their multifaceted activity, we investigated the antibacterial, antifungal, and antidermatophytal profiles of derivatives <b>1-9</b>, highlighting a new promising research line. Furthermore, the ability of these compounds to inhibit selected microbial and human carbonic anhydrases (CAs) was assessed, revealing their possible involvement in the MoA and a good selectivity index for some derivatives.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>D'Agostino</LastName>
            <ForeName>Ilaria</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4870-7326</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathew</LastName>
            <ForeName>Githa Elizabeth</ForeName>
            <Initials>GE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Grace College of Pharmacy, Palakkad, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angelini</LastName>
            <ForeName>Paola</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0002-6862-1079</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Venanzoni</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <Identifier Source="ORCID">0000-0002-7768-0468</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angeles Flores</LastName>
            <ForeName>Giancarlo</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry, Biology and Biotechnology, University of Perugia, Perugia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Angeli</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-1470-7192</Identifier>
            <AffiliationInfo>
              <Affiliation>Neurofarba Department, University of Florence, Sesto Fiorentino, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Carradori</LastName>
            <ForeName>Simone</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-8698-9440</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marinacci</LastName>
            <ForeName>Beatrice</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menghini</LastName>
            <ForeName>Luigi</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-7346-7395</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelgawad</LastName>
            <ForeName>Mohamed A</ForeName>
            <Initials>MA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ghoneim</LastName>
            <ForeName>Mohammed M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, Faculty of Pharmacy, AlMaarefa University, Ad Diriyah, Saudi Arabia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mathew</LastName>
            <ForeName>Bijo</ForeName>
            <Initials>B</Initials>
            <Identifier Source="ORCID">0000-0002-6658-4497</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Supuran</LastName>
            <ForeName>Claudiu T</ForeName>
            <Initials>CT</Initials>
            <Identifier Source="ORCID">0000-0003-4262-0323</Identifier>
            <AffiliationInfo>
              <Affiliation>Neurofarba Department, University of Florence, Sesto Fiorentino, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Enzyme Inhib Med Chem</MedlineTA>
        <NlmUniqueID>101150203</NlmUniqueID>
        <ISSNLinking>1475-6366</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D002257">Carbonic Anhydrase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013882">Thiosemicarbazones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 4.2.1.1</RegistryNumber>
          <NameOfSubstance UI="D002256">Carbonic Anhydrases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001419" MajorTopicYN="N">Bacteria</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002257" MajorTopicYN="N">Carbonic Anhydrase Inhibitors</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002256" MajorTopicYN="N">Carbonic Anhydrases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005658" MajorTopicYN="N">Fungi</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013882" MajorTopicYN="N">Thiosemicarbazones</DescriptorName>
          <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Escherichia coli</Keyword>
        <Keyword MajorTopicYN="N">Thiosemicarbazones</Keyword>
        <Keyword MajorTopicYN="N">antimicrobial agents</Keyword>
        <Keyword MajorTopicYN="N">carbonic anhydrases</Keyword>
        <Keyword MajorTopicYN="N">dermatophytes</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. No potential conflict of interest was reported by all authors. CT Supuran is Editor-in-Chief of the Journal of Enzyme Inhibition and Medicinal Chemistry. He was not involved in the assessment, peer review, or decision-making process of this paper. The authors have no relevant affiliations of financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>8</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35322729</ArticleId>
        <ArticleId IdType="pmc">PMC8956313</ArticleId>
        <ArticleId IdType="doi">10.1080/14756366.2022.2055009</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Addressing the crisis in antibiotic development . Accessed in January 2022. Available from: https://www.who.int/news/item/09-07-2020-addressing-the-crisis-in-antibiotic-development.</Citation>
        </Reference>
        <Reference>
          <Citation>Pulingam T, Parumasivam T, Gazzali AM, et al. . 
Antimicrobial resistance: prevalence, economic burden, mechanisms of resistance and strategies to overcome. Eur J Pharm Sci
2022;170:106103. https://linkinghub.elsevier.com/retrieve/pii/S0928098721004048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34936936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baghdadi JD, Coffey KC, Adediran T, et al. . 
Antibiotic use and bacterial infection among inpatients in the first wave of COVID-19: a Retrospective Cohort Study of 64,691 patients. Antimicrob Agents Chemother
2021;65:PMC8522758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8522758</ArticleId>
            <ArticleId IdType="pubmed">34491806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi SG, Ahammad SZ.. 
COVID-19 and antimicrobial resistance: a cross-study. Sci Total Environ
2022;807:150873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8500695</ArticleId>
            <ArticleId IdType="pubmed">34634340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lobie TA, Roba AA, Booth JA, et al. . 
Antimicrobial resistance: a challenge awaiting the post-COVID-19 era. Int J Infect Dis
2021;111:322–5. https://pubmed.ncbi.nlm.nih.gov/34508864/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8425743</ArticleId>
            <ArticleId IdType="pubmed">34508864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafran N, Shafran I, Ben-Zvi H, et al. . 
Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. Sci Rep
2021;11:1–8. https://www.nature.com/articles/s41598-021-92220-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8209102</ArticleId>
            <ArticleId IdType="pubmed">34135459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Westblade LF, Simon MS, Satlin MJ.. 
Bacterial coinfections in Coronavirus Disease 2019. Trends Microbiol
2021;29:930–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8026275</ArticleId>
            <ArticleId IdType="pubmed">33934980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segrelles-Calvo G, de S Araújo GR, Llopis-Pastor E, et al. . 
Candida spp. co-infection in COVID-19 patients with severe pneumonia: prevalence study and associated risk factors. Respir Med
202;188:106619. http://www.resmedjournal.com/article/S0954611121003279/fulltext.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8445759</ArticleId>
            <ArticleId IdType="pubmed">34555702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moser D, Biere K, Han B, et al. . 
COVID-19 impairs immune response to Candida albicans. Front Immunol
2021;12:250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953065</ArticleId>
            <ArticleId IdType="pubmed">33717195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khurana A, Sardana K, Chowdhary A.. 
Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol
2019;132:103255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31330295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sacheli R, Hayette M-P, Rodrigues CF, et al. . 
Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies. J Fungi
2021;7:983. https://www.mdpi.com/2309-608X/7/11/983/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8622014</ArticleId>
            <ArticleId IdType="pubmed">34829270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patrick MT, Zhang H, Wasikowski R, et al. . 
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol
2021;147:857–69.e7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7825803</ArticleId>
            <ArticleId IdType="pubmed">33485957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products . Accessed in January 2022. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products.</Citation>
        </Reference>
        <Reference>
          <Citation>Analysis Shows Continued Deficiencies in Antibiotic Development since 2014  | The Pew Charitable Trusts. Accessed in January 2022. Available from: https://www.pewtrusts.org/en/research-and-analysis/data-visualizations/2019/five-year-analysis-shows-continued-deficiencies-in-antibiotic-development.</Citation>
        </Reference>
        <Reference>
          <Citation>Which pathogens are receiving most attention in R&amp;D? – Access to  Medicine Foundation. Accessed in January 2022. Available from: https://accesstomedicinefoundation.org/amr-benchmark/results/which-pathogens-are-receiving-most-attention-in-r-d.</Citation>
        </Reference>
        <Reference>
          <Citation>Campestre C, De Luca V, Carradori S, et al. . 
Carbonic anhydrases: new perspectives on protein functional role and inhibition in Helicobacter pylori. Front Microbiol
2021;12:551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8017301</ArticleId>
            <ArticleId IdType="pubmed">33815311</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Capasso C.. 
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Expert Opin Ther Pat
2020;30:963–82..</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32806966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Supuran CT, Capasso C.. 
An overview of the bacterial carbonic anhydrases. Metabolites
2017;7:56. https://www.mdpi.com/2218-1989/7/4/56/htm.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5746736</ArticleId>
            <ArticleId IdType="pubmed">29137134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flaherty DP, Seleem MN, Supuran CT.. 
Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets. Future Med Chem
2021;13:1619–22. https://www.future-science.com/doi/abs/10.4155/fmc-2021-0207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/fmc-2021-0207</ArticleId>
            <ArticleId IdType="pmc">PMC8656345</ArticleId>
            <ArticleId IdType="pubmed">34382415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grande R, Carradori S, Puca V, et al. . 
Selective inhibition of helicobacter pylori carbonic anhydrases by Carvacrol and thymol could impair biofilm production and the release of outer membrane vesicles. Int J Mol Sci
2021;22:11583. Available from: https://www.mdpi.com/1422-0067/22/21/11583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8584244</ArticleId>
            <ArticleId IdType="pubmed">34769015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Güzel-Akdemir Ö, Carradori S, Grande R, et al. . 
Development of thiazolidinones as fungal carbonic anhydrase inhibitors. Int J Mol Sci
2020;21:2960. https://www.mdpi.com/1422-0067/21/8/2960/htm.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7215574</ArticleId>
            <ArticleId IdType="pubmed">32331447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cottier F, Leewattanapasuk W, Kemp LR, et al. . 
Carbonic anhydrase regulation and CO(2) sensing in the fungal pathogen Candida glabrata involves a novel Rca1p ortholog. Bioorg Med Chem
2013;21:1549–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22727373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Capasso C, Supuran CT.. 
Bacterial, fungal and protozoan carbonic anhydrases as drug targets. Expert Opin Ther Targets
2015;19:1689–704. https://pubmed.ncbi.nlm.nih.gov/26235676/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26235676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hewitt CS, Abutaleb NS, Elhassanny AEM, et al. . 
Structure-activity relationship studies of acetazolamide-based carbonic anhydrase inhibitors with activity against neisseria gonorrhoeae. ACS Infect Dis
2021;7:1969–84. https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.1c00055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsinfecdis.1c00055</ArticleId>
            <ArticleId IdType="pmc">PMC8317129</ArticleId>
            <ArticleId IdType="pubmed">33765392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abutaleb NS, Elkashif A, Flaherty DP, et al. . 
In vivo antibacterial activity of acetazolamide. Antimicrob Agents Chemother
2021;65:e01715–20. https://pubmed.ncbi.nlm.nih.gov/33495225/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8097480</ArticleId>
            <ArticleId IdType="pubmed">33495225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaur J, Cao X, Abutaleb NS, et al. . 
Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus. J Med Chem
2020;63:9540–62. https://pubmed.ncbi.nlm.nih.gov/32787141/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8317130</ArticleId>
            <ArticleId IdType="pubmed">32787141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abutaleb NS, Elhassanny AEM, Flaherty DP, et al. . 
In vitro and in vivo activities of the carbonic anhydrase inhibitor, dorzolamide, against vancomycin-resistant enterococci. PeerJ
2021;9:e11059. https://pubmed.ncbi.nlm.nih.gov/33850651/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8018244</ArticleId>
            <ArticleId IdType="pubmed">33850651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbanski LJ, Bua S, Angeli A, et al. . 
Sulphonamide inhibition profile of Staphylococcus aureus β-carbonic anhydrase. J Enzyme Inhib Med Chem
2020;35:1834–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7534311</ArticleId>
            <ArticleId IdType="pubmed">32972256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urbanski LJ, Vullo D, Parkkila S, et al. . 
An anion and small molecule inhibition study of the β-carbonic anhydrase from Staphylococcus aureus. J Enzyme Inhib Med Chem
2021;36:1088–92. https://pubmed.ncbi.nlm.nih.gov/34056990/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8168783</ArticleId>
            <ArticleId IdType="pubmed">34056990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prete SD, De Luca V, Bua S, et al. . 
The effect of substituted benzene-sulfonamides and clinically licensed drugs on the catalytic activity of CynT2, a carbonic anhydrase crucial for escherichia coli life cycle. Int J Mol Sci
2020;21:4175. https://www.mdpi.com/1422-0067/21/11/4175/htm.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7312386</ArticleId>
            <ArticleId IdType="pubmed">32545297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete S, De Luca V, De Luca V, et al. . 
Anion inhibition studies of the beta-carbonic anhydrase from Escherichia coli. Molecules
2020;25:2564. https://www.mdpi.com/1420-3049/25/11/2564/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7321114</ArticleId>
            <ArticleId IdType="pubmed">32486444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murray AB, Aggarwal M, Pinard M, et al. . 
Structural mapping of anion inhibitors to β-carbonic anhydrase psCA3 from Pseudomonas aeruginosa. Chem Med Chem
2018;13:2024–9. https://pubmed.ncbi.nlm.nih.gov/30088334/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30088334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinard MA, Lotlikar SR, Boone CD, et al. . 
Structure and inhibition studies of a type II beta-carbonic anhydrase psCA3 from Pseudomonas aeruginosa. Bioorg Med Chem
2015;23:4831–8. https://pubmed.ncbi.nlm.nih.gov/26068018/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26068018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angeli A, Pinteala M, Maier SS, et al. . 
Inhibition of bacterial α-, β- and γ-class carbonic anhydrases with selenazoles incorporating benzenesulfonamide moieties. J Enzyme Inhib Med Chem
2019;34:244–9. https://pubmed.ncbi.nlm.nih.gov/30734601/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6327980</ArticleId>
            <ArticleId IdType="pubmed">30734601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>More MS, Joshi PG, Mishra YK, et al. . 
Metal complexes driven from Schiff bases and semicarbazones for biomedical and allied applications: a review. Mater Today Chem
2019;14:100195.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7110249</ArticleId>
            <ArticleId IdType="pubmed">32289101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oliveira AA, Oliveira APA, Franco LL, et al. . 
5-Nitroimidazole-derived Schiff bases and their copper(II) complexes exhibit potent antimicrobial activity against pathogenic anaerobic bacteria. BioMetals
2018;31:571–84. https://link.springer.com/article/10.1007/s10534-018-0106-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10534-018-0106-6</ArticleId>
            <ArticleId IdType="pubmed">29736775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bisceglie F, Bacci C, Vismarra A, et al. . 
Antibacterial activity of metal complexes based on cinnamaldehyde thiosemicarbazone analogues. J Inorg Biochem
2020;203:110888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31783215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pham VH, Dung Phan TP, Phan DC, et al. . 
Synthesis and bioactivity of thiosemicarbazones containing adamantane skeletons. Molecules
2020;25:324. https://www.mdpi.com/1420-3049/25/2/324/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7024387</ArticleId>
            <ArticleId IdType="pubmed">31941142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Zhang ZM, Li MX.. 
Synthesis, characterization, and biological activity of cadmium (II) and antimony (III) complexes based on 2-acetylpyrazine thiosemicarbazones. Inorg Chim Acta
2022;530:120671.</Citation>
        </Reference>
        <Reference>
          <Citation>Carradori S, Chimenti P, Fazzari M, et al. . 
Antimicrobial activity, synergism and inhibition of germ tube formation by Crocus sativus-derived compounds against Candida spp. J Enzyme Inhib Med Chem
2016;31:189–93. https://www.tandfonline.com/doi/abs/10.1080/14756366.2016.1180596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14756366.2016.1180596</ArticleId>
            <ArticleId IdType="pubmed">27160150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaushal M, Lobana TS, Nim L, et al. . 
Synthesis of 2-acetylpyridine-N-substituted thiosemicarbazonates of copper(II) with high antimicrobial activity against methicillin resistant S. aureus, K. pneumoniae 1 and C. albicans. New J Chem
2019;43:11727–42. https://pubs.rsc.org/en/content/articlehtml/2019/nj/c9nj01459d.</Citation>
        </Reference>
        <Reference>
          <Citation>Ameryckx A, Pochet L, Wang G, et al. . 
Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting D-alanyl-D-alanine ligase in bacterio. Eur J Med Chem
2020; 200:112444. https://www.sciencedirect.com/science/article/pii/S0223523420304153?via%3Dihub.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32497961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reis DC, Despaigne AAR, Da Silva JG, et al. . 
Structural studies and investigation on the activity of imidazole-derived thiosemicarbazones and hydrazones against crop-related fungi. Molecules
2013;18:12645–62. https://www.mdpi.com/1420-3049/18/10/12645/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6270485</ArticleId>
            <ArticleId IdType="pubmed">24129274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussein M, Hussein MB, Mohammed MM, et al. . 
Synthesis, characterization, and antimicrobial activity of 4-imidazolecarboxaldehyde thiosemicarbazone and its Pt(II) and Pd(II) complexes. Eur J Chem
2021;12:56–9. https://www.eurjchem.com/index.php/eurjchem/article/view/2070.</Citation>
        </Reference>
        <Reference>
          <Citation>Bajaj K, Buchanan RM, Grapperhaus CA.. 
Antifungal activity of thiosemicarbazones, bis(thiosemicarbazones), and their metal complexes. J Inorg Biochem
2021;225:111620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34619407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carradori S, Secci D, D’Ascenzio M, et al. . 
Microwave and ultrasound-assisted synthesis of thiosemicarbazones and their corresponding (4,5-Substituted-thiazol-2-yl)hydrazines. J Heterocycl Chem
2014;51:1856–61. https://onlinelibrary.wiley.com/doi/full/10.1002/jhet.1856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jhet.1856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathew B, Baek SC, Parambi DGT, et al. . 
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. Med Chem Comm
2018;9:1871–81. https://pubs.rsc.org/en/content/articlehtml/2018/md/c8md00399h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6254048</ArticleId>
            <ArticleId IdType="pubmed">30568755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mathew GE, Oh JM, Mohan K, et al. . 
Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease. J Biomol Struct Dyn
2021;39:4786–94. https://www.tandfonline.com/doi/abs/10.1080/07391102.2020.1782266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/07391102.2020.1782266</ArticleId>
            <ArticleId IdType="pubmed">32588753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain J, Sanwaria AR, Gopal R, et al. . 
Synthesis and characterisation of zinc and cadmium thiosemicarbazones: potential precursors for nano sized metal oxides/sulphides. Mater Res Innov
2022;26:36–43. https://www.tandfonline.com/doi/abs/10.1080/14328917.2021.1880736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14328917.2021.1880736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Blanden A, Tsang AT, et al. . 
Thiosemicarbazones functioning as zinc metallochaperones to reactivate mutant p53. Mol Pharmacol
2017;91:567–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5438133</ArticleId>
            <ArticleId IdType="pubmed">28320780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Islam M, Khan A, Shehzad MT, et al. . 
Synthesis and characterization of new thiosemicarbazones, as potent urease inhibitors: in vitro and in silico studies. Bioorg Chem
2019;87:155–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30884309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noruzi EB, Shaabani B, Geremia S, et al. . 
Synthesis, crystal structure, and biological activity of a multidentate Calix[4]arene ligand doubly functionalized by 2-Hydroxybenzeledene-thiosemicarbazone. Molecules
2020;25:370. https://www.mdpi.com/1420-3049/25/2/370/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7024204</ArticleId>
            <ArticleId IdType="pubmed">31963211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaber A, Refat MS, Belal AAM, et al. . 
New mononuclear and binuclear Cu(II), Co(II), Ni(II), and Zn(II) thiosemicarbazone complexes with potential biological activity: antimicrobial and molecular docking study. Molecules
2021;26:2288. https://www.mdpi.com/1420-3049/26/8/2288/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8071257</ArticleId>
            <ArticleId IdType="pubmed">33920893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for Bacteria That Grow Aerobically. Approved Standard, 10th ed.; CLSI Document M07-A10; Wayne (PA): Clinical and Laboratory Standards Institute; 2015.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute . Reference method for broth dilution antifungal susceptibility testing of yeast, 4th ed.; CLSI Standard M27. Wayne (PA): Clinical and Laboratory Standards Institute; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute . Performance standards for antifungal susceptibility testing of yeasts, 1st ed.; CLSI Supplement M60. Wayne (PA): Clinical and Laboratory Standards Institute; 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Clinical and Laboratory Standards Institute . Reference method for broth dilution antifungal susceptibility testing of Filamentous Fungi, 2nd ed.; CLSI Document M38-A2. Wayne (PA): Clinical and Laboratory Standards Institute; 2008.</Citation>
        </Reference>
        <Reference>
          <Citation>Angelini P, Matei F, Flores GA, et al. . 
Metabolomic profiling, antioxidant and antimicrobial activity of Bidens pilosa. Processes
2021;9:903.</Citation>
        </Reference>
        <Reference>
          <Citation>Ferrante C, Angelini P, Venanzoni R, et al. . 
Antimicrobial, antioxidant, and antiproliferative effects of Coronilla minima: an unexplored botanical species. Antibiotics
2020;9:611. https://www.mdpi.com/2079-6382/9/9/611/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7560210</ArticleId>
            <ArticleId IdType="pubmed">32957623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelini P, Pellegrino RM, Tirillini B, et al. . 
Metabolomic profiling and biological activities of Pleurotus columbinus Quél. Cultivated on different agri-food byproducts. Antibiotics
2021;10:1245. Available from: https://www.mdpi.com/2079-6382/10/10/1245/html.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8532797</ArticleId>
            <ArticleId IdType="pubmed">34680825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luca V, Petreni A, Carginale V, et al. . 
Effect of amino acids and amines on the activity of the recombinant ι-carbonic anhydrase from the Gram-negative bacterium Burkholderia territorii. J Enzyme Inhib Med Chem
2021;36:1000–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8128165</ArticleId>
            <ArticleId IdType="pubmed">33980103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Prete S, Bua S, Supuran CT, et al. . 
Escherichia coliγ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem
2020;35:1545–54. https://www.tandfonline.com/doi/abs/10.1080/14756366.2020.1800670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14756366.2020.1800670</ArticleId>
            <ArticleId IdType="pmc">PMC7470111</ArticleId>
            <ArticleId IdType="pubmed">32746656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimori I, Minakuchi T, Morimoto K, et al. . 
Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem
2006;49:2117–26. https://pubs.acs.org/doi/full/10.1021/jm0512600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm0512600</ArticleId>
            <ArticleId IdType="pubmed">16539401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimori I, Minakuchi T, Kohsaki T, et al. . 
Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors. Bioorg Med Chem Lett
2007;17:3585–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17482815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Awale M, Reymond JL.. 
Polypharmacology browser PPB2: target prediction combining nearest neighbors with machine learning. J Chem Inf Model
2019;59:10–7. https://pubmed.ncbi.nlm.nih.gov/30558418/.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30558418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akdemir A, Angeli A, Göktaş F, et al. . 
Novel 2-indolinones containing a sulfonamide moiety as selective inhibitors of candida β-carbonic anhydrase enzyme. J Enzyme Inhib Med Chem
2019;34:528–31. https://www.tandfonline.com/doi/abs/10.1080/14756366.2018.1564045.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14756366.2018.1564045</ArticleId>
            <ArticleId IdType="pmc">PMC6366411</ArticleId>
            <ArticleId IdType="pubmed">30724625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kjxalifah RG.
The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes b and c. J Biol Chem
1971;246:2561–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4994926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Wang L, Lv M, et al. . 
AlzPlatform: an Alzheimer’s disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research. J Chem Inf Model
2014;54:1050–60. https://pubs.acs.org/doi/abs/10.1021/ci500004h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ci500004h</ArticleId>
            <ArticleId IdType="pmc">PMC4010297</ArticleId>
            <ArticleId IdType="pubmed">24597646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daina A, Michielin O, Zoete V.. 
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep
2017;7:42717–3. https://www.nature.com/articles/srep42717.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5335600</ArticleId>
            <ArticleId IdType="pubmed">28256516</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
